Here are five things to know:
1. The company’s BRTX-100 is a novel autologous stem cell product to designed to treat degenerative disc disease.
2. In February 2017, BioRestorative received FDA clearance to begin a phase 2 clinical trial of BRTX-100.
3. The phase 2 trial is expected to start in the first quarter of 2019.
4. The company appointed Wayne J. Olan, MD, as clinical director of its regenerative disc/spine program.
5. BioRestorative also developed the ThermoStem program to treat metabolic disorders, including diabetes and obesity.
More articles on biologics:
1st patient enrolled in Cerapedics’ TLIF clinical trial: 5 takeaways
Who are the 10 key players in the $226B spine biologics market?
206 Ortho gets bio-inspired patent: 3 quick notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
